Default Category
-
A Managerial Perspective on Clinical Trials
Daemmrich, Arthur A.Case HBS-709033-EEntrepreneurshipThis note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70 percent of a drug's total development costs, pharmaceutical and biotechnology leaders need to understand clinical trial management. Likewise, with a growing variety of new product i...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change (Abridged)
Daemmrich, Arthur A.Case HBS-711050-EArcadia Biosciences is seeking to introduce genetically modified rice to China that will lower farmers' costs and generate environmental benefits through reduced greenhouse gas emissions. The case describes challenges facing this small agricultural biotechnology company, notably uneven enforcement of intellectual property in emerging market countries, and uncertainty regarding the provision and market value of carbon credits under international c...Starting at €8.20
-
Novozymes: Cracking the Emerging Markets Code
Palepu, Krishna G.; Misztal, KarolCase HBS-112084-EIn 2011, the management of Novozymes, the industrial enzymes leader, reflected on the viability of their positioning in the fast growing, yet increasingly competitive Chinese market. Novozymes, a technological innovation pioneer, was prominent in China's premium enzyme markets, but felt pressure from local low-cost rivals in volume-driven, commoditized segments. How should Novozymes relate to local competitors? By competing on technological innov...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change
Daemmrich, Arthur A.; Reinhardt, Forest L.; Shelman, MaryCase HBS-709019-EArcadia Biosciences is an entrepreneurial California agricultural biotech company seeking to earn carbon credits by modifying commodity crops for use in China and India. Eric Rey, Arcadia's CEO, faced a strategic inflection point in early September, 2008. The company had a plan to share carbon credits allocated by the United Nations Clean Development Mechanism Executive Board to China, for use of Arcadia's rice varieties, since they enabled farme...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change, Teaching Note
Daemmrich, Arthur A.; Reinhardt, Forest L.Teaching Note HBS-711042-ETeaching Note for 709019.Starting at €0.00
-
Investindustrial Exits Ducati
Brochet, Francois; Misztal, KarolCase HBS-113058-EAccounting and ControlIn early 2012, Investindustrial, a European private equity group, publicly announced their intention to sell their 76.7% stake in Ducati Motor Holding S.p.A., an iconic Italian producer of sport performance motorcycles. The decision followed a six-year turnaround during which Ducati returned to profitability and significantly expanded its product line. Investindustrial's team had the following exit alternatives: 1) a trade sale to an automotive b...Starting at €8.20
-
The IASB at a Crossroads: The Future of International Financial Reporting Standards B
Ramanna, Karthik; Misztal, Karol; Beyersdorfer, DanielaCase HBS-113089-EAccounting and ControlSupplement for case 111084. In late 2012, IASB chair Hans Hoogervorst, just over a year into his term, must address several serious geopolitical challenges that can derail IFRS growth. The SEC has issued a report outlining why the U.S. should not adopt IFRS. Other major economies such as Japan and India begin to dither on IFRS as well. The E--the IASB's main backers--is embroiled in a debt crisis that divides it; Britain--the strongest voice for ...Starting at €8.20